With $3bn Viela Acquisition, Horizon Builds A Pipeline

Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.

building construction
Horizon is growing with the acquisition of Viela • Source: Shuterstock

Horizon Therapeutics plc is expanding its rare disease portfolio and pipeline with the acquisition of Viela Bio, Inc. for $3.05bn, looking to build on the success Horizon has experienced with the launch of Tepezza (teprotumumab) last year for thyroid eye disease. The acquisition of Viela will substantially bolster Horizon's portfolio, adding one commercial product, Uplizna (inebilizumab) for a rare autoimmune condition, and three pipeline products.

"This transaction represents a significant step forward in our transformation to an innovation-driven, high-growth biotech company," CEO Tim Walbert said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip